The PubMed entry records the article titled “Beyond Heart Rate: Interpreting the Hemodynamic Response to Ivabradine in Pediatric Cardiac Critical Care,” authored by Fabio Savorgnan and published online ahead of print in the American Journal of Therapeutics. The entry lists DOI 10.1097/MJT.0000000000002202 and PubMed PMID 42557609, with an online date of 2026 Aug 6.
This citation-level information is provided to help clinicians and librarians locate the full text for detailed review. The DOI and PMID are included on the PubMed page to facilitate retrieval from publisher platforms or institutional subscriptions.
Fabio Savorgnan is affiliated with the Division of Critical Care Medicine, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX. The PubMed record includes a conflict of interest statement: the author declares no conflicts of interest.
The PubMed record explicitly states: “No abstract available.” As a result, the entry does not provide the paper’s objectives, methods, patient population, measured hemodynamic endpoints, results, or conclusions.
Because the PubMed summary lacks an abstract, readers cannot assess study design, sample size, statistical analyses, or safety and efficacy findings from the record alone. Clinicians and researchers should obtain and review the full-text article via the DOI or journal website to examine the primary data and any recommendations before applying them in clinical practice.
The article’s title indicates a focus on interpreting the hemodynamic response to ivabradine in the setting of pediatric cardiac critical care. This signals that the paper addresses more than heart rate reduction alone and considers broader circulatory or perfusion effects in critically ill pediatric cardiac patients.
However, because the PubMed entry does not include the abstract or body content, the specific topics covered (for example, which hemodynamic parameters were assessed, whether the context was post-operative care, heart failure, or arrhythmia management, or whether invasive monitoring was used) are not reported in this record.
The PubMed page links to related items that provide context and may be useful for clinicians seeking evidence about ivabradine’s hemodynamic effects in children and other models. The PubMed entry lists a referenced study relevant to this topic:
Additional similar articles and related work are listed on the PubMed page; these can be consulted to build a more complete evidence base while the full text of the Savorgnan article is retrieved.
Retrieval: Use the DOI (10.1097/MJT.0000000000002202) or PubMed PMID (42557609) to obtain the full-text article through institutional access, interlibrary loan, or the publisher’s platform to review study details.
Evaluate methods and endpoints: Because no abstract is provided in the PubMed entry, clinicians should examine the full text to determine study design, patient selection, ivabradine dosing, timing relative to critical illness or surgery, hemodynamic measures used, and reported safety signals.
Cross-reference: Consult the cited and similar articles listed on the PubMed page (for example, the Loomba et al. 2026 Am J Ther report) to compare findings and contextualize any claims about ivabradine’s effects beyond heart rate reduction.
Apply cautiously: Until the full article is reviewed, do not change clinical practice based on the PubMed entry alone. The lack of an abstract means that important details necessary for safe and effective application are not available in the public summary.
Acknowledgment of source limitations
All statements in this summary are limited to the information available on the PubMed record for PMID 42557609. Specific study data, results, and author conclusions were not reported in the PubMed entry; therefore they are not summarized here. For comprehensive clinical interpretation, consult the full-text article.